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Summary Epidermal growth factor receptors (EGFr) were measured using a radioligand binding assay, in
membrane preparations from 51 human non-small cell lung cancers and in normal tissue of the same patients.
The binding characteristics of EGFr were similar in tumour and normal lung membranes (range of
dissociation constant of high affinity sites: 0.1-0.6 nM). However, the concentrations in tumours (median,
16.4 fmol mgI of protein; range, 1.5-176) were significantly higher than in normal tissues (median, 7.4 fmol
mg-' of protein; range, 1.9-13.4).
The receptor levels in normal tissue were normally distributed. It was therefore possible to define a
normal/pathologic cut-off level (12.9 fmol mg-' of protein). In 57% of cases EGFr in cancer was higher than
the cut-off. No relationships were found between receptor concentrations and positivity rates of EGFr and
histology, stage, lymph node positivity and pT. A trend for a direct relation between receptor positivity and
grading was found.
Epidermal Growth Factor receptor (EGFr) is a 170,000-Da
transmembrane glycoprotein with an intracellular domain
that contains intrinsic tyrosine kinase activity (Carpenter,
1983; Gill et al., 1987). The enzymatic activity stimulated by
EGF binding is directed against several protein substrates
and the receptor itself (Hunter & Cooper, 1981; Cooper et
al., 1982; Downward et al., 1984), and result in regulating the
growth and differentiation of many ectodermal-derived cells
(Carpenter & Cohen, 1979).
Some evidences suggest that EGFr could be related to
malignant transformation. Indeed, transforming growth fac-
tor alpha (TGF(x), a peptide produced by transformed cells,
was shown to stimulate the growth of malignant tissues
through binding to the EGFr (Reynolds et al., 1981; Nickell
et al., 1983). EGFr sequence is related to erb-B2 oncogen
product, a membrane protein with receptor function, and to
v-erbB product, which represents the intracellular domain of
EGFr.
Many studies show that EGFr may play a role in the
development of different ectodermal-derived malignancies.
High concentrations of EGFr were found in tumours of the
nervous system (Libermann et al., 1984), bladder (Neal et al.,
1985) and head and neck (Ishitoya et al., 1989). High levels
of EGFr in breast cancer have been related to a poorer
prognosis (Sainsbury et al., 1987).
The presence of EGFr in lung cancer has been reported in
non-small cell lung cancer (NSCLC) tissue samples (Berger et
al., 1987; Cerny et al., 1986; Dazzi et al., 1989; Hendler &
Ozanne, 1984; Sobol et al., 1987; Hwang et al., 1986; Veale et
al., 1987; Veale et al., 1989). The absence of the EGFr
(Hendler & Ozanne, 1984; Sobol et al., 1987) and EGFr gene
expression (Gamou et al., 1987) was indeed demonstrated in
small cell lung cancer (SCLC) samples. The study of the
relationships between EGFr and both grade of differentiation
and histological type led to conflicting results (Berger et al.,
1987; Cerny et al., 1986; Dazzi et al., 1989; Veale et al., 1987;
Veale et al., 1989).
EGFr concentration was found to be higher in cancer than
in normal lung tissue. However, the analysis of EGFr in
normal lung samples was so far performed only in a limited
number of cases (Hwang et al., 1986; Veale et al., 1987; Veale
et al., 1989).
The EGFr in the present investigation has been assayed
both in cancer and in normal tissue from 51 patients with
primary resectable NSCLC. The aim of the study was to
evaluate the differences of EGFr expression between lung
cancer and normal lung tissue, as well as the relationship
between EGFr expression and other pathological parameters.
Patients and methods
Patients
To date, 51 patients with primary NSCLC have been evaluat-
ed (median age: 60 years, range 47-78; squamous cell car-
cinomas 64%, adenocarcinomas 27%, large cell carcinomas
9%; stage I 62%, stage II 7%, stage III 31%). Patients were
staged and pathological T (pT) was determined according to
UICC criteria (UICC, 1979). Histologic typing was per-
formed following WHO criteria (WHO, 1981). Sample of
both tumour tissue and apparently normal lung tissue, at
least 10 cm apart from the tumour, were collected freshly at
the time of operation from each patient.
Samples were washed several times with cold isotonic
saline solution (4°C), minced, quick frozen, and stored in
liquid nitrogen.
Procedures
Membrane preparation and EGFr assay were performed as
previously described (Dittadi et al., 1990). Supercooled tissue
samples were pulverised, homogenised in Tris buffer and
centrifuged at 800 g for 10 min at 4°C. The pellet was washed
twice more and the supernatants pooled and centrifuged at
100,000g for 1 h at 4°C. The membrane pellet was incubated
with 0.5 nm final concentration of human '25I-EGF prepared
by lactoperoxidase method (S.A. 1,000-1,400 Ci mmolP '
Amersham, UK). The concentration used for the binding
analysis ranged from 6 to 0.06 nm. The determination of
non-specific binding was performed by using cold human
EGF (Amersham) at a concentration 100 time the maximal
'251I-EGF dose. The mixture was incubated 20 h at 260C,
centrifuged at 5,000g for 30min, the supernatant was dis-
carded and the pellet was counted in a T-counter.
The total protein concentration was measured by the Brad-
ford protein-dye binding method (Bradford, 1976).
Results were expressed as fmoles of EGFr per mg of
membrane protein (m.p.).
Statistical analysis was performed using Kolmogorov-
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Smirnov, Wilcoxon rank sum, Kruskal-Wallis and Chi-
square tests.
Results
A preliminary analysis of EGFr binding characteristics was
performed both in tumour and in normal tissues samples.
Results, determined by Feldman analysis (Feldman, 1972),
indicate the presence of two classes of binding sites in all the
20 specimens analysed. The range of the dissociation con-
stant (Kd) was 0.1-0.6nM in the high affinity sites, and
2.1-6.3 nM in the low affinity sites. One example of a typical
Scathard plot is shown in Figure 1. Binding characteristics
were not significantly different between cancer and normal
tissues.
To quantify the EGFr in small tissue specimens, we used a
single dose of 1251I-EGF (0.5 nM), sufficient to saturate high
affinity sites, assayed in triplicate.
EGFr concentrations found in the 102 tissue samples
examined are summarised in Table I.
In normal lung tissue the concentrations of EGFr are
normally distributed (Figure 2), whereas in cancer tissue the
EGFr concentrations show an asymmetrical distribution
(Figure 3).
On the basis of EGFr distribution in normal lung tissue
samples we calculated a normal/pathologic cut-off point,
which resulted in 12.9 fmoles/mg m.p. (mean of EGFr con-
centration in normal lung + 2 s.d.). EGFr in lung cancer was
therefore evaluated both as a continuous quantitative para-
meter and as a dichotomic variable (positive/negative).
EGFr levels in 41/51 cancer samples were higher than in
the normal tissue of the same patient (Table II). Fifty-seven
per cent of cases showed EGFr levels above the cut-off point
and could be therefore considered as EGFr positive.
.
No significant relationships were found between EGFr and
histologic type, lymph node status, clinical stage and pT
(Table III). A trend for a direct relation between receptor
positivity and grading were found (Table III).
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Table I EGFr concentrations in lung membranes (fmoles
membrane protein)
Normal Cancer
Mean 7.4 23.5
s.d. 2.7 27.0
Median 7.4 16.4
Range 1.9-13.4 1.5-176
Number of cases 51 51
Wilcoxon rank-sum test: P = 0.0002.
Cases
P.L.
R.P.
P.B.
M.G.
C.G.
S.S.
V.G.
S.M.
D.R.
F.O.
700 G.E.
C.M.
M.G.
r memb- O.A.
v affinity P.B.
P.B.
R.G.
O.A.
P.G.
smg-' of G.I.
G.L.
Z.A.
F.G.
B.C.
G.G.
C.I.
Histology
A
SCC
SCC
SCC
A
U
SCC
SCC
A
SCC
SCC
U
LC
A
SCC
SCC
A
SCC
SCC
SCC
A
SCC
A
SCC
U
A
EGFra
N C
3.6 8.1
5.7 23.8
8.0 12.7
2.2 4.6
9.8 22.4
7.2 3.1
8.1 45.4
8.3 24.9
4.1 19.7
8.7 16.9
2.5 25.0
5.2 3.4
10.1 18.1
10.8 6.0
7.2 24.1
8.0 41.3
11.0 4.4
9.7 7.6
5.5 37.5
5.7 29.0
6.9 1.5
4.9 5.2
1.9 7.0
5.2 35.9
3.0 9.8
3.0 17.0
Cases
L.B.
C.S.
R.G.
P.S.
C.A.
T.L.
D.G.
P.L.
P.A.
C.S.
M.O.
S.I.
V.E.
B.C.
G.M.
F.C.
O.G.
D.M.
F.G.
F.B.
B.G.
S.E.
S.A.
F.G.
B.M.
Histology
A
A
SCC
SCC
U
A
SCC
A
A
LC
SCC
SCC
SCC
SCC
LC
SCC
SCC
SCC
SCC
SCC
U
LC
SCC
SCC
U
EGFra
N C
9.8 16.4
9.1 36.4
4.6 45.0
7.0 14.9
9.4 9.7
11.8 10.3
7.4 8.7
9.0 27.5
7.1 35.7
5.9 40.0
6.4 15.5
6.5 8.8
7.4 65.7
12.0 32.1
8.2 13.6
13.4 3.2
11.4 26.5
4.7 8.0
12.1 75.1
7.9 6.4
8.9 36.5
4.9 12.1
9.0 175.6
7.1 9.9
7.5 9.1
SCC: Squamous cellcarcinomas; A: adenocarcinoma; LC: large cells
carcinoma; U: unknown; N: normal tissue; C: cancer tissue.
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Table HI EGFr in lung cancer. Relationship to clinical and
pathological parameters
EGFr
Number ofcases Median Interquartile range
+ - P fmolesmg- m.p. P
Stage
1 14 12 14.5 8.5-35.6
2 3 0 0.30 23.8 0.51
3 8 5 16.9 6.6-30.3
Histology
Squamous 18 10 23.9 8.7-36.9
Adenocarcinomas 7 6 0.46 16.4 6.5-24.9 0.35
Large cell 3 1 15.8 12.5-34.5
Grading
GI 0 3 9.7
G2 18 13 0.06 16.4 8.1-27.5 0.11
G3 11 4 25.0 12.1-37.5
Lymph node
0 16 14 14.5 8.1-32.9
11 4 0.20 17.0 9.7-35.7 0.50
pT
1 4 3 16.4 6.4-27.5
2 17 13 0.85 16.2 9.0-35.6 0.87
3 5 3 21.0 3.5-37.0
Discussion
In the present investigation the evaluation of EGFr has been
carried out in both lung cancer and histologically proven
normal lung tissue samples, collected from lung bearing the
tumour.
The number of normal lung tissue evaluated in the present
study is higher than the total number of cases reported in so
far published studies (Hwang et al., 1986; Veale et al., 1987;
Veale et al., 1989). It was therefore possible to compare both
the binding characteristics and the distribution of EGFr con-
centrations between cancer and normal tissue using a number
of cases adequate for statistical evaluation.
The binding characteristics of EGFr were similar in nor-
mal tissue and in cancer, showing a presence of two binding
sites with different affinities, as previously noted both in cell
cultures (Schlessinger, 1988; King & Cuatrecasas, 1982) and
in lung tissues (Veale et al., 1989).
From the binding studies we could determine the 1251I-EGF
concentration capable of saturating the high affinity sites
(0.5 nM), which can be used in a single saturating dose assay
when small tissue samples are available.
In the cancer tissue receptor levels (range 1.5-176 fmol
mg' of protein) are higher than in normal lung (range
1.9-13.4 fmol mg'- of protein). These findings confirm pre-
liminary observations reported by Hwang et al. (1986) on six
cases, by Veale et al. (1987) on 17 cases and by Veale et al.
(1989) on eight cases. In 80% of cases the concentrations in
cancer are higher than in the normal tissue from the same
patient. Considering that EGFr concentrations were found to
be very high in fetal lung (Nexo & Kryger-Baggesen, 1989),
the increased expression of EGFr in lung cancer could be a
consequence of tissue dedifferentiation, and could regulate
the tumour growth by an autocrine mechanism.
The distribution pattern in normal lung tissue was Gaus-
sian, suggesting that EGFr in lung tissue could be physio-
logically expressed. This finding allows for the calculation of
a normal/pathologic cut-off point that could be used to
classify cancer samples even when the normal tissue is not
available.
We did not find significant differences in EGFr concentra-
tions between squamous cell carcinomas, adenocarcinomas
and large cell carcinomas, which is in agreement with the
previous studies carried out with binding methods (Hwang et
al., 1986; Veale et al., 1989). Instead, immunohistochemical
studies report conflicting results. Hendler et al. (1984) found
EGFr only in squamous cell carcinomas. Other authors
found EGFr in all the NSCLCs, with higher concentrations
in squamous carcinomas (Berger et al., 1987; Sobol et al.,
1987; Veale et al., 1987) or without significative differences
between histological types (Cerny et al., 1986; Dazzi et al.,
1989). However, immunohistochemical methods do not allow
for a precise quantification and, in particular for EGFr,
seems to be less sensitive to binding saturation assays (Sobol
et al., 1987; Veale et al., 1989).
The attempt to establish the relationships between EGFr
and other known prognostic factors led to conflicting results.
Higher concentrations in stage III tumours have been found
(Veale et al., 1987), but these results were not confirmed by
the same authors in a following report carried out by a
saturation binding assay (Veale et al., 1989). Dazzi et al.
(1989), in a retrospective study performed by immunohis-
tochemical method, found a higher expression of EGFr in
well differentiated tumour.
However, the EGFr positivity was so far established on the
basis of the sensitivity of assays or semiquantitative classi-
fications.
In this study, the finding of Gaussian distribution in nor-
mal tissue allowed us to define the EGFr positivity in lung
cancer on the basis of a physiologically and statistically
acceptable cut-off point. No relationships were found
between EGFr concentrations or positivity rates and the
prognostic parameters evaluated. A possible independent
prognostic role of EGFr could be therefore postulated.
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